[{"orgOrder":0,"company":"CureVac","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Oncology","graph2":"Discovery","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"CureVac \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MDG2011","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Medigene"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ariceum Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Ariceum Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"IBM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boehringer Ingelheim GmbH \/ IBM","highestDevelopmentStatusID":"2","companyTruncated":"Boehringer Ingelheim GmbH \/ IBM"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Debio 0228","moa":"CA IX","graph1":"Oncology","graph2":"Discovery","graph3":"3B Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3B Pharmaceuticals \/ Debiopharm","highestDevelopmentStatusID":"2","companyTruncated":"3B Pharmaceuticals \/ Debiopharm"},{"orgOrder":0,"company":"Veraxa Biotech","sponsor":"Voyager Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Merger","leadProduct":"VX-A902","moa":"HER2","graph1":"Oncology","graph2":"Discovery","graph3":"Veraxa Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veraxa Biotech \/ Voyager Acquisition Corp","highestDevelopmentStatusID":"2","companyTruncated":"Veraxa Biotech \/ Voyager Acquisition Corp"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The combined company will focus on the development of a comprehensive pipeline of next-generation cancer therapies, including novel ADC, VX-A902, and Bispecific TCE candidates.

                          Product Name : VX-A902

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          April 23, 2025

                          Lead Product(s) : VX-A902

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Voyager Acquisition Corp

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to advance T cell receptor immunotherapies against cancer

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 21, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : BioNTech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Lead Product(s) : mRNA-Based Vaccine

                          Therapeutic Area : Oncology

                          Study Phase : Discovery

                          Sponsor : The University of Texas MD Anderson Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : A collaboration aims to develop mRNA-based cancer vaccines for high unmet needs in hematological and solid cancers, with MD Anderson leading phase 1/2 studies.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : mRNA-Based Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : The University of Texas MD Anderson Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the collaboration, Boehringer will use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 29, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : IBM

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 12, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Evotec

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The agreement aims to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies. LCB has worldwide exclusive rights to develop and commercialize the selected antibody as an ADC...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 16, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : LegoChem Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the collaboration, UCB’s proprietary mRNA-display platform, ExtremeDiversity™ and Ariceum’s expertise in radiopharmaceuticals & labelling technology will enable discovery of peptide-radioisotope conjugates as potential therapeutics for immune...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : UCB Pharma S.A

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.

                          Product Name : MDG2011

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 18, 2023

                          Lead Product(s) : MDG2011

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the expanded collaboration, the companies will develop the pipeline of molecular glue degraders. The companies will leverage all of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $200.0 million

                          March 28, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $5,200.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Evotec has significantly scaled up its activities to develop compounds from BMS’s industry-leading library of cereblon E3 ligase modulators and continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $200.0 million

                          March 16, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $5,200.0 million

                          Deal Type : Partnership

                          blank